Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Korean J Intern Med
Main Authors: Oh, Jae Young, Kim, Byung Seok, Lee, Chang Hyeong, Song, Jeong Eun, Lee, Heon Ju, Park, Jung Gil, Hwang, Jae Seok, Chung, Woo Jin, Jang, Byoung Kuk, Kweon, Young Oh, Tak, Won Young, Park, Soo Young, Jang, Se Young, Suh, Jeong Ill, Kwak, Sang Gyu
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Association of Internal Medicine 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6610199/
https://ncbi.nlm.nih.gov/pubmed/29792020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2017.368
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados